Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG acquires innovative compounds for use in treating cardiac and renal disease

BTG : 10 October, 2006  (Company News)
BTG, the global technology commercialisation company, has obtained exclusive rights from Genentech, Inc. to develop and commercialise an Atrial Natriuretic Factor peptide technology, shown to have therapeutic potential in treating acute congestive heart failure, acute renal failure and renal hypertension. BTG is seeking to license this technology.
The ANF technology consists of synthetic peptides which mimic the naturally occurring ANF hormone and regulate diuretic, natriuretic and vasodilatory activity in mammals. In addition, synthetic ANF is not cleared as quickly from the body as other synthetic peptides, which results in increased metabolic stability and therefore greater efficacy.

Congestive heart failure, a potentially life-threatening disorder with no known cure, is a chronic condition in which the heart functions ineffectively and circulation to the bodys organs is reduced. Each year 15 million people worldwide, including five million Americans, suffer from congestive heart failure. Each year, in the US alone, there are one million hospitalisations due to congestive heart failure, at a cost of $8-15 billion, and approximately 250,000 deaths from congestive heart failure and its complications.

Acute renal failure is characterised by a rapid decline in kidney function which leads to a toxic build-up of metabolic waste products in the blood. The most common causes are diabetes and high blood pressure.

Dr Geoffrey Porges, BTGs Executive Vice President and Director, Health, Medical & BioTechnologies, said: 'The therapeutic potential of these peptides is widely recognised, and there is a need to overcome the weaknesses of current ANF compounds. We are offering potential licensees the opportunity to develop and commercialise these novel human synthetic peptides, which have the potential to treat a number of pathological conditions more effectively than existing technologies.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo